Acrivon Therapeutics (ACRV) News Today → DON’T buy gold until you read this (From Sasco Gold LLC) (Ad) Free ACRV Stock Alerts $7.56 +0.31 (+4.28%) (As of 06/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 9 at 3:19 AM | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six haveMay 29, 2024 | globenewswire.comAcrivon Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 17, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) to Post Q2 2024 Earnings of ($0.48) Per Share, HC Wainwright ForecastsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2024 earnings estimates for Acrivon Therapeutics in a report issued on Tuesday, May 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.48) per sMay 15, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Stock Rating Reaffirmed by BMO Capital MarketsBMO Capital Markets reissued an "outperform" rating and issued a $25.00 price objective on shares of Acrivon Therapeutics in a research note on Wednesday.May 15, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from BrokeragesAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buyMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)May 14, 2024 | investorplace.comACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comAcrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 11, 2024 | morningstar.comAcrivon Therapeutics Inc ACRVMay 9, 2024 | finance.yahoo.comWhile institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownershipApril 30, 2024 | msn.comLadenburg Thalmann Downgrades Acrivon Therapeutics (ACRV)April 29, 2024 | marketbeat.comLADENBURG THALM/SH SH Lowers Acrivon Therapeutics (NASDAQ:ACRV) to NeutralLADENBURG THALM/SH SH downgraded Acrivon Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday.April 26, 2024 | markets.businessinsider.comBuy Rating on Acrivon Therapeutics with Increased Target Price Amid Promising ACR-368 Trial DataApril 26, 2024 | morningstar.comAcrivon Therapeutics' shares climb 14% on plans to present cancer-test dataApril 26, 2024 | marketbeat.comBMO Capital Markets Raises Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $25.00BMO Capital Markets lifted their price target on Acrivon Therapeutics from $18.00 to $25.00 and gave the stock an "outperform" rating in a research report on Friday.April 25, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy Recommendation on Impressive AP3 Platform and ACR-368 Data ValidationApril 25, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market PotentialApril 25, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Price Target Raised to $17.00 at JMP SecuritiesJMP Securities upped their price objective on Acrivon Therapeutics from $14.00 to $17.00 and gave the company a "market outperform" rating in a research note on Thursday.April 25, 2024 | marketbeat.comTrading was temporarily halted for "ACRV" at 09:04 AM with a stated reason of "LULD pause."April 25, 2024 | marketbeat.comTrading was temporarily halted for "ACRV" at 09:04 AM with a stated reason of "LULD pause."April 25, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Acrivon Therapeutics in a report on Thursday.April 24, 2024 | msn.comAcrivon Therapeutics’ shares climb 14% on plans to present cancer-test dataApril 24, 2024 | globenewswire.comAcrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D EventApril 20, 2024 | finance.yahoo.comAcrivon Therapeutics, Inc. (ACRV)April 16, 2024 | finance.yahoo.comAcrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316April 16, 2024 | insidertrades.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Buys $20,000,500.00 in StockApril 15, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Acquires $20,000,500.00 in StockAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) major shareholder Perceptive Advisors Llc purchased 2,353,000 shares of the company's stock in a transaction dated Thursday, April 11th. The shares were acquired at an average price of $8.50 per share, for a total transaction of $20,000,500.00. Following the purchase, the insider now directly owns 5,360,858 shares of the company's stock, valued at approximately $45,567,293. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.April 12, 2024 | marketbeat.comEquities Analysts Issue Forecasts for Acrivon Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:ACRV)Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Equities researchers at HC Wainwright cut their Q1 2024 EPS estimates for shares of Acrivon Therapeutics in a research note issued to investors on Tuesday, April 9th. HC Wainwright analyst E. Bodnar now forecasts that the company will postApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acrivon Therapeutics on Promising Drug Pipeline and Solid FinancialsApril 10, 2024 | globenewswire.comAcrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368April 9, 2024 | markets.businessinsider.comAcrivon To Privately Place $130 Mln Of Shares; Stock Soars In Pre-marketApril 9, 2024 | msn.comAcrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?April 9, 2024 | investorplace.comACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million BoostApril 9, 2024 | globenewswire.comAcrivon Therapeutics Announces $130 Million Private Placement FinancingApril 5, 2024 | marketbeat.comLADENBURG THALM/SH SH Lowers Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $14.00LADENBURG THALM/SH SH lowered their price objective on Acrivon Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Friday.April 1, 2024 | marketbeat.comBMO Capital Markets Reiterates Outperform Rating for Acrivon Therapeutics (NASDAQ:ACRV)BMO Capital Markets reiterated an "outperform" rating and issued a $18.00 price objective on shares of Acrivon Therapeutics in a research note on Monday.April 1, 2024 | markets.businessinsider.comBuy Rating on Acrivon Therapeutics: Anticipated Clinical Validation and Strong Financial PositionMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acrivon Therapeutics Amid Anticipated Clinical Updates and Platform PotentialMarch 29, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Expected to Earn Q1 2024 Earnings of ($0.88) Per ShareAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, March 28th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share ofMarch 29, 2024 | markets.businessinsider.comBuy Rating Justified by Acrivon Therapeutics’ Clinical Progress and Market PotentialMarch 29, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy on Promising Clinical Trials and Innovative Drug DevelopmentMarch 28, 2024 | investorplace.comACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023March 28, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Acrivon Therapeutics (NASDAQ:ACRV)HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Acrivon Therapeutics in a research report on Thursday.March 28, 2024 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 28, 2024 | benzinga.comAcrivon Therapeutics: Q4 Earnings InsightsMarch 28, 2024 | globenewswire.comAcrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 5, 2024 | globenewswire.comAcrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316March 4, 2024 | finance.yahoo.comAcrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of DirectorsMarch 2, 2024 | msn.comJMP Securities Initiates Coverage of Acrivon Therapeutics (ACRV) with Market Outperform RecommendationMarch 1, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been assigned an average rating of "Buy" from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-mo Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Hurry! Buy this stock before the Robinhood traders do! (Ad)Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here. Click here to pay just $5 for a full year of Stealth Trades ACRV Media Mentions By Week ACRV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRV News Sentiment▼1.170.76▲Average Medical News Sentiment ACRV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRV Articles This Week▼11▲ACRV Articles Average Week Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ARS Pharmaceuticals News Today Immunome News Today ABIVAX Société Anonyme News Today Centessa Pharmaceuticals News Today Cogent Biosciences News Today Stoke Therapeutics News Today Ocular Therapeutix News Today 89bio News Today PureTech Health News Today Zentalis Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRV) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored